Sleepiness and sleep disordered breathing in Prader-Willi syndrome

Relationship to genotype, growth hormone therapy, and body composition

Korwyn Williams, Ann Scheimann, Vernon Sutton, Elizabeth Hayslett, Daniel G. Glaze

Research output: Contribution to journalArticle

Abstract

Study Objectives: Patients with Prader-Willi syndrome (PWS) suffer from excessive sleepiness and sleep disordered breathing (SDB). We reviewed the polysomnograms (PSGs) and multiple sleep latency tests (MSLTs) in a cohort of PWS patients to determine the relationship of BMIz scores, daytime sleepiness, growth hormone (GH) treatments, and SDB. Methods: Attended overnight PSGs were performed for PWS patients referred for concern for SDB between January 2000 and January 2005. Age at time of study, genotype, use and dose of GH, sleepiness scale, normalized body-mass index (BMIz), total sleep time, latency to stage I and REM sleep, sleep stage percentages, apnea-hypopnea index (AHI), central apnea (CA) frequency, oxygen saturation nadir, maximum carbon dioxide tension, periodic limb movement index, presence of snoring, normality of EEG, and, in several patients, mean sleep latency testing were determined. Results: All patients exhibited some form of SDB. There was a positive correlation between the BMIz and AHI. The BMIz was significantly different between GH-treated and -untreated groups, but there was not a significant difference between AHI, CA, oxygen nadir, or maximum carbon dioxide tension of the GH-treated and -untreated groups. There was no significant correlation between the MSLT and the sleepiness scale or AHI. There was also no significant difference between the AHIs of patients with different genetic defects. Conclusions: There should be a low threshold for obtaining PSG to evaluate SDB, but the type and severity of SDB were not predictable based on a sleepiness scale score, BMIz, or underlying genetic defect.

Original languageEnglish (US)
Pages (from-to)111-118
Number of pages8
JournalJournal of Clinical Sleep Medicine
Volume4
Issue number2
StatePublished - Apr 15 2008

Fingerprint

Prader-Willi Syndrome
Sleep Apnea Syndromes
Body Composition
Growth Hormone
Genotype
Apnea
Sleep
Central Sleep Apnea
Carbon Dioxide
Therapeutics
Oxygen
Snoring
Time and Motion Studies
Sleep Stages
REM Sleep
Electroencephalography
Body Mass Index
Extremities

Keywords

  • Breathing, sleep-disordered
  • Growth hormone
  • Obstructive sleep apnea
  • Polysomnography
  • Prader-Willi syndrome
  • Snoring

ASJC Scopus subject areas

  • Clinical Neurology
  • Pulmonary and Respiratory Medicine
  • Neurology

Cite this

Sleepiness and sleep disordered breathing in Prader-Willi syndrome : Relationship to genotype, growth hormone therapy, and body composition. / Williams, Korwyn; Scheimann, Ann; Sutton, Vernon; Hayslett, Elizabeth; Glaze, Daniel G.

In: Journal of Clinical Sleep Medicine, Vol. 4, No. 2, 15.04.2008, p. 111-118.

Research output: Contribution to journalArticle

@article{d9c813154e46468f8cfe620a95db4523,
title = "Sleepiness and sleep disordered breathing in Prader-Willi syndrome: Relationship to genotype, growth hormone therapy, and body composition",
abstract = "Study Objectives: Patients with Prader-Willi syndrome (PWS) suffer from excessive sleepiness and sleep disordered breathing (SDB). We reviewed the polysomnograms (PSGs) and multiple sleep latency tests (MSLTs) in a cohort of PWS patients to determine the relationship of BMIz scores, daytime sleepiness, growth hormone (GH) treatments, and SDB. Methods: Attended overnight PSGs were performed for PWS patients referred for concern for SDB between January 2000 and January 2005. Age at time of study, genotype, use and dose of GH, sleepiness scale, normalized body-mass index (BMIz), total sleep time, latency to stage I and REM sleep, sleep stage percentages, apnea-hypopnea index (AHI), central apnea (CA) frequency, oxygen saturation nadir, maximum carbon dioxide tension, periodic limb movement index, presence of snoring, normality of EEG, and, in several patients, mean sleep latency testing were determined. Results: All patients exhibited some form of SDB. There was a positive correlation between the BMIz and AHI. The BMIz was significantly different between GH-treated and -untreated groups, but there was not a significant difference between AHI, CA, oxygen nadir, or maximum carbon dioxide tension of the GH-treated and -untreated groups. There was no significant correlation between the MSLT and the sleepiness scale or AHI. There was also no significant difference between the AHIs of patients with different genetic defects. Conclusions: There should be a low threshold for obtaining PSG to evaluate SDB, but the type and severity of SDB were not predictable based on a sleepiness scale score, BMIz, or underlying genetic defect.",
keywords = "Breathing, sleep-disordered, Growth hormone, Obstructive sleep apnea, Polysomnography, Prader-Willi syndrome, Snoring",
author = "Korwyn Williams and Ann Scheimann and Vernon Sutton and Elizabeth Hayslett and Glaze, {Daniel G.}",
year = "2008",
month = "4",
day = "15",
language = "English (US)",
volume = "4",
pages = "111--118",
journal = "Journal of Clinical Sleep Medicine",
issn = "1550-9389",
publisher = "American Academy of Sleep Medicine",
number = "2",

}

TY - JOUR

T1 - Sleepiness and sleep disordered breathing in Prader-Willi syndrome

T2 - Relationship to genotype, growth hormone therapy, and body composition

AU - Williams, Korwyn

AU - Scheimann, Ann

AU - Sutton, Vernon

AU - Hayslett, Elizabeth

AU - Glaze, Daniel G.

PY - 2008/4/15

Y1 - 2008/4/15

N2 - Study Objectives: Patients with Prader-Willi syndrome (PWS) suffer from excessive sleepiness and sleep disordered breathing (SDB). We reviewed the polysomnograms (PSGs) and multiple sleep latency tests (MSLTs) in a cohort of PWS patients to determine the relationship of BMIz scores, daytime sleepiness, growth hormone (GH) treatments, and SDB. Methods: Attended overnight PSGs were performed for PWS patients referred for concern for SDB between January 2000 and January 2005. Age at time of study, genotype, use and dose of GH, sleepiness scale, normalized body-mass index (BMIz), total sleep time, latency to stage I and REM sleep, sleep stage percentages, apnea-hypopnea index (AHI), central apnea (CA) frequency, oxygen saturation nadir, maximum carbon dioxide tension, periodic limb movement index, presence of snoring, normality of EEG, and, in several patients, mean sleep latency testing were determined. Results: All patients exhibited some form of SDB. There was a positive correlation between the BMIz and AHI. The BMIz was significantly different between GH-treated and -untreated groups, but there was not a significant difference between AHI, CA, oxygen nadir, or maximum carbon dioxide tension of the GH-treated and -untreated groups. There was no significant correlation between the MSLT and the sleepiness scale or AHI. There was also no significant difference between the AHIs of patients with different genetic defects. Conclusions: There should be a low threshold for obtaining PSG to evaluate SDB, but the type and severity of SDB were not predictable based on a sleepiness scale score, BMIz, or underlying genetic defect.

AB - Study Objectives: Patients with Prader-Willi syndrome (PWS) suffer from excessive sleepiness and sleep disordered breathing (SDB). We reviewed the polysomnograms (PSGs) and multiple sleep latency tests (MSLTs) in a cohort of PWS patients to determine the relationship of BMIz scores, daytime sleepiness, growth hormone (GH) treatments, and SDB. Methods: Attended overnight PSGs were performed for PWS patients referred for concern for SDB between January 2000 and January 2005. Age at time of study, genotype, use and dose of GH, sleepiness scale, normalized body-mass index (BMIz), total sleep time, latency to stage I and REM sleep, sleep stage percentages, apnea-hypopnea index (AHI), central apnea (CA) frequency, oxygen saturation nadir, maximum carbon dioxide tension, periodic limb movement index, presence of snoring, normality of EEG, and, in several patients, mean sleep latency testing were determined. Results: All patients exhibited some form of SDB. There was a positive correlation between the BMIz and AHI. The BMIz was significantly different between GH-treated and -untreated groups, but there was not a significant difference between AHI, CA, oxygen nadir, or maximum carbon dioxide tension of the GH-treated and -untreated groups. There was no significant correlation between the MSLT and the sleepiness scale or AHI. There was also no significant difference between the AHIs of patients with different genetic defects. Conclusions: There should be a low threshold for obtaining PSG to evaluate SDB, but the type and severity of SDB were not predictable based on a sleepiness scale score, BMIz, or underlying genetic defect.

KW - Breathing, sleep-disordered

KW - Growth hormone

KW - Obstructive sleep apnea

KW - Polysomnography

KW - Prader-Willi syndrome

KW - Snoring

UR - http://www.scopus.com/inward/record.url?scp=47849086593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47849086593&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 111

EP - 118

JO - Journal of Clinical Sleep Medicine

JF - Journal of Clinical Sleep Medicine

SN - 1550-9389

IS - 2

ER -